Cilostazol dramatically reduces Toll-like receptor 4 (TLR4) expression in synovial phagocytes derived from RA cases via inhibiting the Purine-rich box1 (PU.1) transcriptional activity (He et al. 2020; Carlaf and Brito 2020). The gene discussed is TLR4; the disease is rheumatoid arthritis.